Amedisys Inc - AMED STOCK NEWS

Amedisys (NASDAQ: AMED) has released its Q4 and full-year 2024 financial results. Q4 net service revenue increased to $598.1 million, up from $570.8 million in 2023. However, the company reported a Q4 net loss of $20.4 million, impacted by $17.4 million in merger-related expenses and a $48.4 million non-cash goodwill impairment charge.

For the full year 2024, net service revenue grew to $2,348.3 million from $2,236.4 million in 2023. The company achieved net income of $43.2 million, despite incurring $66.6 million in merger-related expenses. Adjusted EBITDA for 2024 was $245.8 million, slightly down from $247.0 million in 2023. Adjusted earnings per share reached $4.32, compared to $4.30 in 2023.

Amedisys (NASDAQ: AMED) has awarded its prestigious Spirit of Excellence Awards to 47 outstanding employees from its workforce of over 19,000 nationwide. The awards recognize exceptional performance across multiple categories including Home Health, Hospice, Acute Care, Palliative Care, and Corporate Support roles.

President and CEO Richard Ashworth praised the winners for bringing warmth, compassion, and clinical expertise to patient care. The honorees were selected for their outstanding patient care, ability to inspire patients and families, exceeding role expectations, and encouraging patient self-reliance.

Award categories included Nurses of the Year, Social Workers/Chaplains, Therapists, Clinical Managers, Patient Support Services Professionals, Nurse Peer Mentors, Volunteers, and various specialized roles across Home Health, Hospice, Acute Care, and Palliative Care divisions. Winners represented multiple states including Texas, South Carolina, Virginia, Georgia, Alabama, Tennessee, New York, and Florida, among others.

Amedisys (NASDAQ: AMED) reported its Q3 2024 financial results with net service revenue increasing to $587.7 million, up from $556.2 million in 2023. Net income was $16.9 million ($0.51 per diluted share), compared to $26.0 million ($0.79 per share) in 2023, including merger-related expenses of $16.7 million. For the nine-month period, revenue grew to $1,750.3 million from $1,665.6 million, with net income of $63.6 million compared to a net loss of $29.1 million in 2023. Adjusted EBITDA for Q3 2024 was $58.1 million, slightly up from $57.9 million in 2023.

Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, and high-acuity care, has been recognized by Strategic Healthcare Programs (SHP) for outstanding patient and caregiver satisfaction in 2023. 92 Amedisys care centers received SHPBest™ Patient Satisfaction Awards, with 14 centers earning Premier Performer status (top 5%) and 78 centers achieving Superior Performer status (top 20%). Notably, 13 care centers have maintained award-winning performance for five consecutive years.

The SHPBest™ award program evaluates over 3,200 home health providers and 1,750 hospice providers based on HHCAHPS and CAHPS Hospice survey satisfaction scores. This recognition highlights Amedisys' commitment to delivering exceptional care and maintaining high patient and caregiver satisfaction levels across its network.

Contessa Health, a subsidiary of Amedisys Inc. (Nasdaq: AMED), has been selected by the Centers for Medicare & Medicaid Services (CMS) to participate in the Guiding an Improved Dementia Experience (GUIDE) Model. This new Medicare alternative payment model aims to support people living with dementia and their caregivers. As one of nearly 400 participants, Contessa will build Dementia Care Programs (DCPs) to enhance care coordination and improve access to services.

The GUIDE Model, launched on July 1, 2024, will test a new payment approach for key supportive services, including comprehensive assessments, care coordination, 24/7 access to care team members, and respite services. Contessa's participation will provide dementia patients and caregivers with access to education, support, and respite services, potentially allowing them to live at home longer and achieve a better quality of life.

Amedisys, Inc. (NASDAQ: AMED) reported its financial results for Q2 2024. Net service revenue increased by $38.2 million to $591.2 million compared to Q2 2023. The company reported a net income of $32.3 million, including $11.9 million in merger-related expenses, compared to a net loss of $80.3 million in Q2 2023. Adjusted EBITDA was $73.2 million, slightly down from $74.6 million in 2023. For the six-month period, net service revenue rose to $1,162.6 million, with a net income of $46.7 million. The company's adjusted net income per diluted share for Q2 2024 was $1.32, compared to $1.37 in 2023. Amedisys noted that it will not conduct a quarterly earnings call due to its pending merger with UnitedHealth Group Incorporated.